Placebo to Benralizumab

BIOLOGICAL2 trials

Sponsors

AstraZeneca

Conditions

Eosinophilic Granulomatous VasculitisNon-cystic Fibrosis Bronchiectasis

Phase 3

Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.

Active, not recruitingNCT04157348

AstraZenecaEosinophilic Granulomatous Vasculitis

Start: 2019-10-29End: 2026-11-30Updated: 2026-08-12

Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis

TerminatedNCT05006573

AstraZenecaNon-cystic Fibrosis Bronchiectasis

Start: 2021-07-21End: 2024-04-16Updated: 2025-07-20

Related Papers

Discontinuation of Oral Glucocorticoids and Achievement of Remission in Patients With Eosinophilic Granulomatosis With Polyangiitis Treated With Benralizumab or Mepolizumab

ACR Open Rheumatology2025-08-311 citations

Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis

New England Journal of Medicine2024-02-23137 citations

Bronchiectasis enters the inflammation era

Respirology2022-04-1311 citations